tmp-195 Search Results


94
MedChemExpress tmp195
Senescence-induced glycolysis and lactate accumulation impair autophagy in trophoblasts. ( A ) Heatmap showed the relative expression changes of seven proteins in the glycolysis/gluconeogenesis pathway. ( B ) Glucose and lactate concentrations in the supernatant of senescent HTR-8/SVneo cells treated with or without IL33 (10 ng/mL). ( C and D ) Western blot for SQSTM1 or LC3B-II:I in normal and senescent HTR-8/SVneo cells treated with different concentration of lactate (0, 10, 20 mM for 48 h). Relative expression levels of proteins were standardized using internal reference ACTB. ( E ) The expression of lactylation level was analyzed by immunohistochemistry staining in normal and URPL villi ( n = 6 per group). Scale bar: 200 μm. ( F ) The expression of lactylation level was analyzed by immunohistochemistry staining in wt and il33 −/− mice ( n = 6 per group). Scale bar: 500 μm. ( G ) Western blot for lactylation level in HTR-8/SVneo cell senescence models treated with or without IL33 (10 ng/mL). Relative expression levels of proteins were standardized using internal reference histone H3. ( H ) Western blot for lactylation level in normal and senescent HTR-8/SVneo cells treated with different concentration of lactate (0, 10, 20 mM for 48 h). Relative expression levels of proteins were standardized using internal reference histone H3. ( I ) Western blot for lactylation and acetylation level in trophoblast cells treated with tacedinaline (5 μM, 48 h) or <t>TMP195</t> (5 μM, 48 h). Relative expression levels of proteins were standardized using internal reference histone H3. ( J ) The expression of SQSTM1 was detected by immunofluorescence in HTR-8/SVneo cells treated with tacedinaline (5 μM, 48 h) or TMP195 (5 μM, 48 h). Scale bar: 10 μm. ( K and L ) The level of autophagy was detected by the DAL/DAP fluorescence probes in HTR-8/SVneo cells treated with tacedinaline (5 μM, 48 h) or TMP195 (5 μM, 48 h). Scale bar: 50 μm. Immunofluorescence staining results was quantified with average intensity. All data were generated using ImageJ. Statistical data were presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ns, no significant difference , using two-tailed Student’s t-test (e, F) and one-way ANOVA test (b, d, L).
Tmp195, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tmp-195/TMP195/pmc13285577-412-29-34
Average 94 stars, based on 1 article reviews
tmp195 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

92
TargetMol tmp195
Fig. 7. HDAC9 expression is elevated in AAD aortic tissue. Mechanistically, HDAC9 binds to the promoter regions of SOD2 and IGFBP3, transcriptionally suppressing their expression, forming the HDAC9-SOD2/IGFBP3 axis, regulating the phenotypic transformation, proliferation, apoptosis, and invasion of VSMCs during the process of AAD occurrence. <t>TMP195</t> reverses this process by inhibiting HDAC9, suppressing the formation and development of AAD.
Tmp195, supplied by TargetMol, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tmp-195/TMP195/pm38460370-110-0-4
Average 92 stars, based on 1 article reviews
tmp195 - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

93
Selleck Chemicals tmp159
Fig. 7. HDAC9 expression is elevated in AAD aortic tissue. Mechanistically, HDAC9 binds to the promoter regions of SOD2 and IGFBP3, transcriptionally suppressing their expression, forming the HDAC9-SOD2/IGFBP3 axis, regulating the phenotypic transformation, proliferation, apoptosis, and invasion of VSMCs during the process of AAD occurrence. <t>TMP195</t> reverses this process by inhibiting HDAC9, suppressing the formation and development of AAD.
Tmp159, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tmp-195/TMP195/bio_rxiv__2025__08__01__668069-41-25-26
Average 93 stars, based on 1 article reviews
tmp159 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Axon Medchem LLC tmp 195
Fig. 7. HDAC9 expression is elevated in AAD aortic tissue. Mechanistically, HDAC9 binds to the promoter regions of SOD2 and IGFBP3, transcriptionally suppressing their expression, forming the HDAC9-SOD2/IGFBP3 axis, regulating the phenotypic transformation, proliferation, apoptosis, and invasion of VSMCs during the process of AAD occurrence. <t>TMP195</t> reverses this process by inhibiting HDAC9, suppressing the formation and development of AAD.
Tmp 195, supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tmp-195/tmp195/pmc05842265-49-0-5
Average 90 stars, based on 1 article reviews
tmp 195 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
BioMimetic Therapeutics hdac inhibitor tmp-195
Fig. 7. HDAC9 expression is elevated in AAD aortic tissue. Mechanistically, HDAC9 binds to the promoter regions of SOD2 and IGFBP3, transcriptionally suppressing their expression, forming the HDAC9-SOD2/IGFBP3 axis, regulating the phenotypic transformation, proliferation, apoptosis, and invasion of VSMCs during the process of AAD occurrence. <t>TMP195</t> reverses this process by inhibiting HDAC9, suppressing the formation and development of AAD.
Hdac Inhibitor Tmp 195, supplied by BioMimetic Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tmp-195/nanoparticles+carrying+the+tam+repolarizer+tmp195/pmc09677115-132-12-8
Average 90 stars, based on 1 article reviews
hdac inhibitor tmp-195 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MedKoo Inc tmp195
PLD2 inhibition sensitizes SAHA-induced apoptotic cell death. a MDA-MB-231 cells were transfected with siRNA of PLD2 and then treated with vehicle or SAHA (5 μM) for 36 h. Apoptosis was examined via flow cytometry and presented as the percentage of cells labeled with annexin V-PE. b MDA-MB-231 cells were stained with propidium iodide (1 μg/mL) and the population of subG1 apoptotic cells was determined using FACScan flow cytometry. c MDA-MB231 cells were treated with T247 (3 μM), <t>TMP195</t> (3 μM), and PLD2 inhibitor (10 μM) for 36 h, and caspase-3 activity was examined. d MDA-MB231 were treated with SAHA (5 μM), rapamycin (50 nM), temozolomide (50 μM), and PLD2 inhibitor (10 μM) for 36 h, and caspase-3 activity was examined. e The cells were treated with SAHA, PLD2 inhibitor, or PA (50 μM) for 36 h. Apoptosis using annexin V staining was examined. f MDA-MB-231 cells were treated with the indicated drugs for 36 h, and caspase-3 activity and g expression of the indicated proteins were examined. The intensity of the indicated bands was normalized to the intensity of their respective α-tubulin bands and quantified against each other. Results are representative of at least four independent experiments and shown as the mean ± SEM. ** p < 0.001
Tmp195, supplied by MedKoo Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tmp-195/tmp195/pmc07528251-142-2-5
Average 90 stars, based on 1 article reviews
tmp195 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Glaxo Smith tmp195
<t>TMP195</t> re-sensitizes ABCB1-overexpressing cells to paclitaxel and ABCG2-overexpressing cells to mitoxantrone. The chemosensitization effect of TMP195 was examined by treating cells with increasing concentrations of paclitaxel (a known substrate drug of ABCB1), or mitoxantrone (a known substrate drug of ABCG2) or etoposide (a known substrate drug of ABCC1) in the presence of DMSO (open circles) or TMP195 at 1 μM (open squares), 2 μM (filled squares), 3 μM (open triangles) or 5 μM (filled triangles). ( A ) Drug-sensitive parental KB-3-1 (left panel) and the ABCB1-overexpressing multidrug resistance (MDR) variant KB-V-1 (right panel) human epidermal cancer cells, as well as ( B ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCB1 (MDR1, right panel) were used to determine the effect of TMP195 on ABCB1-mediated paclitaxel resistance. ( C ) Drug-sensitive parental S1 (left panel) and the ABCG2-overexpressing MDR variant S1-M1-80 (right panel) human colon cancer cells, as well as ( D ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCG2 (R482, right panel) were used to determine the effect of TMP195 on ABCG2-mediated mitoxantrone resistance. ( E ) Drug-sensitive parental COR-L23/P (left panel) and the ABCC1-overexpressing MDR variant COR-L23/R (right panel) human lung cancer cells, as well as ( F ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCC1 (MRP1, right panel) were used to determine the effect of TMP195 on ABCC1-mediated etoposide resistance. Points, mean values from at least three independent experiments; error bars, SEM.
Tmp195, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tmp-195/tmp195/pmc06981391-119-0-18
Average 90 stars, based on 1 article reviews
tmp195 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Tempero Pharmaceuticals tmp195
<t>TMP195</t> re-sensitizes ABCB1-overexpressing cells to paclitaxel and ABCG2-overexpressing cells to mitoxantrone. The chemosensitization effect of TMP195 was examined by treating cells with increasing concentrations of paclitaxel (a known substrate drug of ABCB1), or mitoxantrone (a known substrate drug of ABCG2) or etoposide (a known substrate drug of ABCC1) in the presence of DMSO (open circles) or TMP195 at 1 μM (open squares), 2 μM (filled squares), 3 μM (open triangles) or 5 μM (filled triangles). ( A ) Drug-sensitive parental KB-3-1 (left panel) and the ABCB1-overexpressing multidrug resistance (MDR) variant KB-V-1 (right panel) human epidermal cancer cells, as well as ( B ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCB1 (MDR1, right panel) were used to determine the effect of TMP195 on ABCB1-mediated paclitaxel resistance. ( C ) Drug-sensitive parental S1 (left panel) and the ABCG2-overexpressing MDR variant S1-M1-80 (right panel) human colon cancer cells, as well as ( D ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCG2 (R482, right panel) were used to determine the effect of TMP195 on ABCG2-mediated mitoxantrone resistance. ( E ) Drug-sensitive parental COR-L23/P (left panel) and the ABCC1-overexpressing MDR variant COR-L23/R (right panel) human lung cancer cells, as well as ( F ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCC1 (MRP1, right panel) were used to determine the effect of TMP195 on ABCC1-mediated etoposide resistance. Points, mean values from at least three independent experiments; error bars, SEM.
Tmp195, supplied by Tempero Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tmp-195/tmp195/pmc10952174-444-19-8
Average 90 stars, based on 1 article reviews
tmp195 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
CELLAGEN TECHNOLOGY LLC tmp195
<t>TMP195</t> re-sensitizes ABCB1-overexpressing cells to paclitaxel and ABCG2-overexpressing cells to mitoxantrone. The chemosensitization effect of TMP195 was examined by treating cells with increasing concentrations of paclitaxel (a known substrate drug of ABCB1), or mitoxantrone (a known substrate drug of ABCG2) or etoposide (a known substrate drug of ABCC1) in the presence of DMSO (open circles) or TMP195 at 1 μM (open squares), 2 μM (filled squares), 3 μM (open triangles) or 5 μM (filled triangles). ( A ) Drug-sensitive parental KB-3-1 (left panel) and the ABCB1-overexpressing multidrug resistance (MDR) variant KB-V-1 (right panel) human epidermal cancer cells, as well as ( B ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCB1 (MDR1, right panel) were used to determine the effect of TMP195 on ABCB1-mediated paclitaxel resistance. ( C ) Drug-sensitive parental S1 (left panel) and the ABCG2-overexpressing MDR variant S1-M1-80 (right panel) human colon cancer cells, as well as ( D ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCG2 (R482, right panel) were used to determine the effect of TMP195 on ABCG2-mediated mitoxantrone resistance. ( E ) Drug-sensitive parental COR-L23/P (left panel) and the ABCC1-overexpressing MDR variant COR-L23/R (right panel) human lung cancer cells, as well as ( F ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCC1 (MRP1, right panel) were used to determine the effect of TMP195 on ABCC1-mediated etoposide resistance. Points, mean values from at least three independent experiments; error bars, SEM.
Tmp195, supplied by CELLAGEN TECHNOLOGY LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tmp-195/tmp195/pm31732526-79-61-62
Average 90 stars, based on 1 article reviews
tmp195 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Target Molecule Corp tmp195 t3983
<t>TMP195</t> re-sensitizes ABCB1-overexpressing cells to paclitaxel and ABCG2-overexpressing cells to mitoxantrone. The chemosensitization effect of TMP195 was examined by treating cells with increasing concentrations of paclitaxel (a known substrate drug of ABCB1), or mitoxantrone (a known substrate drug of ABCG2) or etoposide (a known substrate drug of ABCC1) in the presence of DMSO (open circles) or TMP195 at 1 μM (open squares), 2 μM (filled squares), 3 μM (open triangles) or 5 μM (filled triangles). ( A ) Drug-sensitive parental KB-3-1 (left panel) and the ABCB1-overexpressing multidrug resistance (MDR) variant KB-V-1 (right panel) human epidermal cancer cells, as well as ( B ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCB1 (MDR1, right panel) were used to determine the effect of TMP195 on ABCB1-mediated paclitaxel resistance. ( C ) Drug-sensitive parental S1 (left panel) and the ABCG2-overexpressing MDR variant S1-M1-80 (right panel) human colon cancer cells, as well as ( D ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCG2 (R482, right panel) were used to determine the effect of TMP195 on ABCG2-mediated mitoxantrone resistance. ( E ) Drug-sensitive parental COR-L23/P (left panel) and the ABCC1-overexpressing MDR variant COR-L23/R (right panel) human lung cancer cells, as well as ( F ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCC1 (MRP1, right panel) were used to determine the effect of TMP195 on ABCC1-mediated etoposide resistance. Points, mean values from at least three independent experiments; error bars, SEM.
Tmp195 T3983, supplied by Target Molecule Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tmp-195/tmp195+t3983/pm34469109-121-0-5
Average 90 stars, based on 1 article reviews
tmp195 t3983 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

N/A
TMP195 is a selective class IIa histone deacetylase (HDAC) inhibitor (IC50s= 59 nM, 60 nM, 26 nM and 15 nM for HDAC4, HDAC5, HDAC7 and HDAC9 respectively), and is >100 fold selective over other HDACs
  Buy from Supplier

N/A
InformationTMP195 TMP195 (TFMO 2) is a selective, first-in-class, class IIa HDAC inhibitor with IC50 of 300 nM in cell-based class IIa HDAC assays.In vitroTMP195 has low potency in recombinant class I and IIb HDAC assays,
  Buy from Supplier

Image Search Results


Senescence-induced glycolysis and lactate accumulation impair autophagy in trophoblasts. ( A ) Heatmap showed the relative expression changes of seven proteins in the glycolysis/gluconeogenesis pathway. ( B ) Glucose and lactate concentrations in the supernatant of senescent HTR-8/SVneo cells treated with or without IL33 (10 ng/mL). ( C and D ) Western blot for SQSTM1 or LC3B-II:I in normal and senescent HTR-8/SVneo cells treated with different concentration of lactate (0, 10, 20 mM for 48 h). Relative expression levels of proteins were standardized using internal reference ACTB. ( E ) The expression of lactylation level was analyzed by immunohistochemistry staining in normal and URPL villi ( n = 6 per group). Scale bar: 200 μm. ( F ) The expression of lactylation level was analyzed by immunohistochemistry staining in wt and il33 −/− mice ( n = 6 per group). Scale bar: 500 μm. ( G ) Western blot for lactylation level in HTR-8/SVneo cell senescence models treated with or without IL33 (10 ng/mL). Relative expression levels of proteins were standardized using internal reference histone H3. ( H ) Western blot for lactylation level in normal and senescent HTR-8/SVneo cells treated with different concentration of lactate (0, 10, 20 mM for 48 h). Relative expression levels of proteins were standardized using internal reference histone H3. ( I ) Western blot for lactylation and acetylation level in trophoblast cells treated with tacedinaline (5 μM, 48 h) or TMP195 (5 μM, 48 h). Relative expression levels of proteins were standardized using internal reference histone H3. ( J ) The expression of SQSTM1 was detected by immunofluorescence in HTR-8/SVneo cells treated with tacedinaline (5 μM, 48 h) or TMP195 (5 μM, 48 h). Scale bar: 10 μm. ( K and L ) The level of autophagy was detected by the DAL/DAP fluorescence probes in HTR-8/SVneo cells treated with tacedinaline (5 μM, 48 h) or TMP195 (5 μM, 48 h). Scale bar: 50 μm. Immunofluorescence staining results was quantified with average intensity. All data were generated using ImageJ. Statistical data were presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ns, no significant difference , using two-tailed Student’s t-test (e, F) and one-way ANOVA test (b, d, L).

Journal: Autophagy

Article Title: Trophoblast aging driven by IL33 deficiency elevates recurrent pregnancy loss risk through SNAP29 lactylation-mediated autophagy impairment

doi: 10.1080/15548627.2026.2659946

Figure Lengend Snippet: Senescence-induced glycolysis and lactate accumulation impair autophagy in trophoblasts. ( A ) Heatmap showed the relative expression changes of seven proteins in the glycolysis/gluconeogenesis pathway. ( B ) Glucose and lactate concentrations in the supernatant of senescent HTR-8/SVneo cells treated with or without IL33 (10 ng/mL). ( C and D ) Western blot for SQSTM1 or LC3B-II:I in normal and senescent HTR-8/SVneo cells treated with different concentration of lactate (0, 10, 20 mM for 48 h). Relative expression levels of proteins were standardized using internal reference ACTB. ( E ) The expression of lactylation level was analyzed by immunohistochemistry staining in normal and URPL villi ( n = 6 per group). Scale bar: 200 μm. ( F ) The expression of lactylation level was analyzed by immunohistochemistry staining in wt and il33 −/− mice ( n = 6 per group). Scale bar: 500 μm. ( G ) Western blot for lactylation level in HTR-8/SVneo cell senescence models treated with or without IL33 (10 ng/mL). Relative expression levels of proteins were standardized using internal reference histone H3. ( H ) Western blot for lactylation level in normal and senescent HTR-8/SVneo cells treated with different concentration of lactate (0, 10, 20 mM for 48 h). Relative expression levels of proteins were standardized using internal reference histone H3. ( I ) Western blot for lactylation and acetylation level in trophoblast cells treated with tacedinaline (5 μM, 48 h) or TMP195 (5 μM, 48 h). Relative expression levels of proteins were standardized using internal reference histone H3. ( J ) The expression of SQSTM1 was detected by immunofluorescence in HTR-8/SVneo cells treated with tacedinaline (5 μM, 48 h) or TMP195 (5 μM, 48 h). Scale bar: 10 μm. ( K and L ) The level of autophagy was detected by the DAL/DAP fluorescence probes in HTR-8/SVneo cells treated with tacedinaline (5 μM, 48 h) or TMP195 (5 μM, 48 h). Scale bar: 50 μm. Immunofluorescence staining results was quantified with average intensity. All data were generated using ImageJ. Statistical data were presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ns, no significant difference , using two-tailed Student’s t-test (e, F) and one-way ANOVA test (b, d, L).

Article Snippet: IL33 (10 ng/mL; PeproTech, 200–33), rapamycin (2 μM, 24 h; Sigma-Aldrich, V900930), lactate (10 or 20 mM, 48 h; Sigma-Aldrich, L6661), tacedinaline (5 μM, 48 h; MedChem Express, HY-50934), TMP195 (5 μM, 48 h; MedChem Express, HY-18361), 2-deoxy-D-glucose (2-DG; 5 or 10 mM, 48 h; MedChem Expres, HY-13966s), Cycloheximide (CHX, 30 μg/mL, 0–8 h; MedChem Express, HY-12320), MG132 (10 μM, 9 h; MedChem Express, HY-13259), bafilomycin A 1 (BafA1, 100 nM, 9 h; MedChem Express, HY-100558) were used.

Techniques: Expressing, Western Blot, Concentration Assay, Immunohistochemistry, Staining, Immunofluorescence, Fluorescence, Generated, Two Tailed Test

Fig. 7. HDAC9 expression is elevated in AAD aortic tissue. Mechanistically, HDAC9 binds to the promoter regions of SOD2 and IGFBP3, transcriptionally suppressing their expression, forming the HDAC9-SOD2/IGFBP3 axis, regulating the phenotypic transformation, proliferation, apoptosis, and invasion of VSMCs during the process of AAD occurrence. TMP195 reverses this process by inhibiting HDAC9, suppressing the formation and development of AAD.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Histone deacetylase 9-mediated phenotypic transformation of vascular smooth muscle cells is a potential target for treating aortic aneurysm/dissection.

doi: 10.1016/j.biopha.2024.116396

Figure Lengend Snippet: Fig. 7. HDAC9 expression is elevated in AAD aortic tissue. Mechanistically, HDAC9 binds to the promoter regions of SOD2 and IGFBP3, transcriptionally suppressing their expression, forming the HDAC9-SOD2/IGFBP3 axis, regulating the phenotypic transformation, proliferation, apoptosis, and invasion of VSMCs during the process of AAD occurrence. TMP195 reverses this process by inhibiting HDAC9, suppressing the formation and development of AAD.

Article Snippet: TMP195 (50 mg/kg; Cat#T3983; TargetMol) or a control solvent (5% DMSO + 30% PEG300 + 5% Tween-80 + 60% Saline) was administered daily via intraperitoneal injection daily for 4 weeks.

Techniques: Expressing, Transformation Assay

PLD2 inhibition sensitizes SAHA-induced apoptotic cell death. a MDA-MB-231 cells were transfected with siRNA of PLD2 and then treated with vehicle or SAHA (5 μM) for 36 h. Apoptosis was examined via flow cytometry and presented as the percentage of cells labeled with annexin V-PE. b MDA-MB-231 cells were stained with propidium iodide (1 μg/mL) and the population of subG1 apoptotic cells was determined using FACScan flow cytometry. c MDA-MB231 cells were treated with T247 (3 μM), TMP195 (3 μM), and PLD2 inhibitor (10 μM) for 36 h, and caspase-3 activity was examined. d MDA-MB231 were treated with SAHA (5 μM), rapamycin (50 nM), temozolomide (50 μM), and PLD2 inhibitor (10 μM) for 36 h, and caspase-3 activity was examined. e The cells were treated with SAHA, PLD2 inhibitor, or PA (50 μM) for 36 h. Apoptosis using annexin V staining was examined. f MDA-MB-231 cells were treated with the indicated drugs for 36 h, and caspase-3 activity and g expression of the indicated proteins were examined. The intensity of the indicated bands was normalized to the intensity of their respective α-tubulin bands and quantified against each other. Results are representative of at least four independent experiments and shown as the mean ± SEM. ** p < 0.001

Journal: Biological Research

Article Title: Inhibition of phospholipase D2 augments histone deacetylase inhibitor-induced cell death in breast cancer cells

doi: 10.1186/s40659-020-00294-3

Figure Lengend Snippet: PLD2 inhibition sensitizes SAHA-induced apoptotic cell death. a MDA-MB-231 cells were transfected with siRNA of PLD2 and then treated with vehicle or SAHA (5 μM) for 36 h. Apoptosis was examined via flow cytometry and presented as the percentage of cells labeled with annexin V-PE. b MDA-MB-231 cells were stained with propidium iodide (1 μg/mL) and the population of subG1 apoptotic cells was determined using FACScan flow cytometry. c MDA-MB231 cells were treated with T247 (3 μM), TMP195 (3 μM), and PLD2 inhibitor (10 μM) for 36 h, and caspase-3 activity was examined. d MDA-MB231 were treated with SAHA (5 μM), rapamycin (50 nM), temozolomide (50 μM), and PLD2 inhibitor (10 μM) for 36 h, and caspase-3 activity was examined. e The cells were treated with SAHA, PLD2 inhibitor, or PA (50 μM) for 36 h. Apoptosis using annexin V staining was examined. f MDA-MB-231 cells were treated with the indicated drugs for 36 h, and caspase-3 activity and g expression of the indicated proteins were examined. The intensity of the indicated bands was normalized to the intensity of their respective α-tubulin bands and quantified against each other. Results are representative of at least four independent experiments and shown as the mean ± SEM. ** p < 0.001

Article Snippet: T247 and TMP195 were from MedKoo Biosciences (Morrisville, NC, USA).

Techniques: Inhibition, Transfection, Flow Cytometry, Labeling, Staining, Activity Assay, Expressing

TMP195 re-sensitizes ABCB1-overexpressing cells to paclitaxel and ABCG2-overexpressing cells to mitoxantrone. The chemosensitization effect of TMP195 was examined by treating cells with increasing concentrations of paclitaxel (a known substrate drug of ABCB1), or mitoxantrone (a known substrate drug of ABCG2) or etoposide (a known substrate drug of ABCC1) in the presence of DMSO (open circles) or TMP195 at 1 μM (open squares), 2 μM (filled squares), 3 μM (open triangles) or 5 μM (filled triangles). ( A ) Drug-sensitive parental KB-3-1 (left panel) and the ABCB1-overexpressing multidrug resistance (MDR) variant KB-V-1 (right panel) human epidermal cancer cells, as well as ( B ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCB1 (MDR1, right panel) were used to determine the effect of TMP195 on ABCB1-mediated paclitaxel resistance. ( C ) Drug-sensitive parental S1 (left panel) and the ABCG2-overexpressing MDR variant S1-M1-80 (right panel) human colon cancer cells, as well as ( D ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCG2 (R482, right panel) were used to determine the effect of TMP195 on ABCG2-mediated mitoxantrone resistance. ( E ) Drug-sensitive parental COR-L23/P (left panel) and the ABCC1-overexpressing MDR variant COR-L23/R (right panel) human lung cancer cells, as well as ( F ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCC1 (MRP1, right panel) were used to determine the effect of TMP195 on ABCC1-mediated etoposide resistance. Points, mean values from at least three independent experiments; error bars, SEM.

Journal: International Journal of Molecular Sciences

Article Title: The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

doi: 10.3390/ijms21010238

Figure Lengend Snippet: TMP195 re-sensitizes ABCB1-overexpressing cells to paclitaxel and ABCG2-overexpressing cells to mitoxantrone. The chemosensitization effect of TMP195 was examined by treating cells with increasing concentrations of paclitaxel (a known substrate drug of ABCB1), or mitoxantrone (a known substrate drug of ABCG2) or etoposide (a known substrate drug of ABCC1) in the presence of DMSO (open circles) or TMP195 at 1 μM (open squares), 2 μM (filled squares), 3 μM (open triangles) or 5 μM (filled triangles). ( A ) Drug-sensitive parental KB-3-1 (left panel) and the ABCB1-overexpressing multidrug resistance (MDR) variant KB-V-1 (right panel) human epidermal cancer cells, as well as ( B ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCB1 (MDR1, right panel) were used to determine the effect of TMP195 on ABCB1-mediated paclitaxel resistance. ( C ) Drug-sensitive parental S1 (left panel) and the ABCG2-overexpressing MDR variant S1-M1-80 (right panel) human colon cancer cells, as well as ( D ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCG2 (R482, right panel) were used to determine the effect of TMP195 on ABCG2-mediated mitoxantrone resistance. ( E ) Drug-sensitive parental COR-L23/P (left panel) and the ABCC1-overexpressing MDR variant COR-L23/R (right panel) human lung cancer cells, as well as ( F ) HEK293 cells (left panel) and HEK293 cells transfected with human ABCC1 (MRP1, right panel) were used to determine the effect of TMP195 on ABCC1-mediated etoposide resistance. Points, mean values from at least three independent experiments; error bars, SEM.

Article Snippet: TMP195 is one of the most potent and highly selective class IIa histone deacetylase (HDAC) inhibitors identified by GlaxoSmithKline in an initiative to discover cell-active class IIa HDAC inhibitors [ ].

Techniques: Variant Assay, Transfection

Effect of  TMP195  on drug resistance mediated by major ATP-binding cassette (ABC) drug efflux transporters in HEK293 cells transfected with ABCB1, ABCC1 or ABCG2.

Journal: International Journal of Molecular Sciences

Article Title: The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

doi: 10.3390/ijms21010238

Figure Lengend Snippet: Effect of TMP195 on drug resistance mediated by major ATP-binding cassette (ABC) drug efflux transporters in HEK293 cells transfected with ABCB1, ABCC1 or ABCG2.

Article Snippet: TMP195 is one of the most potent and highly selective class IIa histone deacetylase (HDAC) inhibitors identified by GlaxoSmithKline in an initiative to discover cell-active class IIa HDAC inhibitors [ ].

Techniques: Transfection, Concentration Assay

Chemosensitizing effect of  TMP195  on multidrug resistance mediated by ABCB1 in ABCB1-overexpressing human cancer cells.

Journal: International Journal of Molecular Sciences

Article Title: The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

doi: 10.3390/ijms21010238

Figure Lengend Snippet: Chemosensitizing effect of TMP195 on multidrug resistance mediated by ABCB1 in ABCB1-overexpressing human cancer cells.

Article Snippet: TMP195 is one of the most potent and highly selective class IIa histone deacetylase (HDAC) inhibitors identified by GlaxoSmithKline in an initiative to discover cell-active class IIa HDAC inhibitors [ ].

Techniques: Concentration Assay

Chemosensitizing effect of  TMP195  on multidrug resistance mediated by ABCG2 in ABCG2-overexpressing human cancer cells.

Journal: International Journal of Molecular Sciences

Article Title: The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

doi: 10.3390/ijms21010238

Figure Lengend Snippet: Chemosensitizing effect of TMP195 on multidrug resistance mediated by ABCG2 in ABCG2-overexpressing human cancer cells.

Article Snippet: TMP195 is one of the most potent and highly selective class IIa histone deacetylase (HDAC) inhibitors identified by GlaxoSmithKline in an initiative to discover cell-active class IIa HDAC inhibitors [ ].

Techniques: Concentration Assay

TMP195 enhances drug-induced apoptosis in ABCB1-overexpressing cancer cells and ABCG2-overexpressing cancer cells. Dot plots (upper panel) and quantification (lower panel) of ( A ) drug-sensitive KB-3-1 cells and the MDR variant KB-V-1 cells treated with either DMSO (control), 10 μM of TMP195 (+TMP195), 500 nM of colchicine (+colchicine), or a combination of 500 nM of colchicine and 10 μM of TMP195 (+colchicine +TMP195), and ( B ) drug-sensitive S1 and the MDR variant S1-M1-80 cells treated with either DMSO (control), 10 μM of TMP195 (+TMP195), 5 μM of topotecan (+topotecan) or a combination of 5 μM of topotecan and 10 μM of TMP195 (+topotecan +TMP195). Cells were treated with respective regimens, isolated, and analyzed by flow cytometry as described previously . Representative dot plots and quantifications of apoptotic cell populations are presented as mean ± SD calculated from at least three independent experiments. ** p < 0.05; ** p < 0.01; *** p < 0.001, versus the same treatment in the absence of TMP195.

Journal: International Journal of Molecular Sciences

Article Title: The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

doi: 10.3390/ijms21010238

Figure Lengend Snippet: TMP195 enhances drug-induced apoptosis in ABCB1-overexpressing cancer cells and ABCG2-overexpressing cancer cells. Dot plots (upper panel) and quantification (lower panel) of ( A ) drug-sensitive KB-3-1 cells and the MDR variant KB-V-1 cells treated with either DMSO (control), 10 μM of TMP195 (+TMP195), 500 nM of colchicine (+colchicine), or a combination of 500 nM of colchicine and 10 μM of TMP195 (+colchicine +TMP195), and ( B ) drug-sensitive S1 and the MDR variant S1-M1-80 cells treated with either DMSO (control), 10 μM of TMP195 (+TMP195), 5 μM of topotecan (+topotecan) or a combination of 5 μM of topotecan and 10 μM of TMP195 (+topotecan +TMP195). Cells were treated with respective regimens, isolated, and analyzed by flow cytometry as described previously . Representative dot plots and quantifications of apoptotic cell populations are presented as mean ± SD calculated from at least three independent experiments. ** p < 0.05; ** p < 0.01; *** p < 0.001, versus the same treatment in the absence of TMP195.

Article Snippet: TMP195 is one of the most potent and highly selective class IIa histone deacetylase (HDAC) inhibitors identified by GlaxoSmithKline in an initiative to discover cell-active class IIa HDAC inhibitors [ ].

Techniques: Variant Assay, Control, Isolation, Flow Cytometry

TMP195 modulates the drug efflux function, but not the protein expression, of ABCB1 and ABCG2 in human multidrug-resistant cancer cells. The effect of TMP195 on ABCB1-mediated transport of calcein-AM, a known substrate of ABCB1, was determined in ( A ) ABCB1-overexpressing KB-V-1 human epidermal cancer cells and ( B ) human HEK293 cells transfected with human ABCB1 (MDR19-HEK293), whereas the effect of TMP195 on ABCG2-mediated transport of pheophorbide A (PhA), a known substrate of ABCG2, was determined in ( C ) ABCG2-overexpressing S1-M1-80 human colon cancer cells and ( D ) HEK293 cells transfected with human ABCG2 (R482-HEK293). Respective drug-sensitive parental cell lines were used as controls (A–D, right panels). Intracellular fluorescence of calcein (A and B) or PhA (C and D) was measured in cells treated with DMSO (A–D, solid lines), 20 μM of TMP195 (A–D, filled solid lines), 20 μM of verapamil as a positive control for ABCB1 inhibition (A and B, dotted lines), or 1 μM of Ko143 as a positive control for ABCG2 inhibition (C and D, dotted lines) as indicated and analyzed by flow cytometry. Representative histograms of at least three independent experiments are shown. The effect of TMP195 on the protein expression of ABCB1 or ABCG2 was determined by treating ( E ) KB-V-1 cancer cells or ( F ) S1-M1-80 cancer cells with increasing concentrations of TMP195 (0–5 μM) as indicated for 72 h before processing for immunoblotting. α-Tubulin was used as an internal loading control. Immunoblot detection (upper panels) and quantification values (lower panels) are presented as mean ± SD calculated from at least three independent experiments.

Journal: International Journal of Molecular Sciences

Article Title: The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

doi: 10.3390/ijms21010238

Figure Lengend Snippet: TMP195 modulates the drug efflux function, but not the protein expression, of ABCB1 and ABCG2 in human multidrug-resistant cancer cells. The effect of TMP195 on ABCB1-mediated transport of calcein-AM, a known substrate of ABCB1, was determined in ( A ) ABCB1-overexpressing KB-V-1 human epidermal cancer cells and ( B ) human HEK293 cells transfected with human ABCB1 (MDR19-HEK293), whereas the effect of TMP195 on ABCG2-mediated transport of pheophorbide A (PhA), a known substrate of ABCG2, was determined in ( C ) ABCG2-overexpressing S1-M1-80 human colon cancer cells and ( D ) HEK293 cells transfected with human ABCG2 (R482-HEK293). Respective drug-sensitive parental cell lines were used as controls (A–D, right panels). Intracellular fluorescence of calcein (A and B) or PhA (C and D) was measured in cells treated with DMSO (A–D, solid lines), 20 μM of TMP195 (A–D, filled solid lines), 20 μM of verapamil as a positive control for ABCB1 inhibition (A and B, dotted lines), or 1 μM of Ko143 as a positive control for ABCG2 inhibition (C and D, dotted lines) as indicated and analyzed by flow cytometry. Representative histograms of at least three independent experiments are shown. The effect of TMP195 on the protein expression of ABCB1 or ABCG2 was determined by treating ( E ) KB-V-1 cancer cells or ( F ) S1-M1-80 cancer cells with increasing concentrations of TMP195 (0–5 μM) as indicated for 72 h before processing for immunoblotting. α-Tubulin was used as an internal loading control. Immunoblot detection (upper panels) and quantification values (lower panels) are presented as mean ± SD calculated from at least three independent experiments.

Article Snippet: TMP195 is one of the most potent and highly selective class IIa histone deacetylase (HDAC) inhibitors identified by GlaxoSmithKline in an initiative to discover cell-active class IIa HDAC inhibitors [ ].

Techniques: Expressing, Transfection, Fluorescence, Positive Control, Inhibition, Flow Cytometry, Western Blot, Control

TMP195 stimulates ATPase activity of ABCB1 and ABCG2. The effect of TMP195 on vanadate-sensitive ATPase activity of ( A ) ABCB1 and ( B ) ABCG2 was determined by the endpoint P i assay as described in the . Data are presented as a mean ± SD from at least three independent experiments as a percentage of basal activity taken as 100%.

Journal: International Journal of Molecular Sciences

Article Title: The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

doi: 10.3390/ijms21010238

Figure Lengend Snippet: TMP195 stimulates ATPase activity of ABCB1 and ABCG2. The effect of TMP195 on vanadate-sensitive ATPase activity of ( A ) ABCB1 and ( B ) ABCG2 was determined by the endpoint P i assay as described in the . Data are presented as a mean ± SD from at least three independent experiments as a percentage of basal activity taken as 100%.

Article Snippet: TMP195 is one of the most potent and highly selective class IIa histone deacetylase (HDAC) inhibitors identified by GlaxoSmithKline in an initiative to discover cell-active class IIa HDAC inhibitors [ ].

Techniques: Activity Assay

Docking of TMP195 in the drug-binding pockets of ABCB1 and ABCG2. Binding modes of TMP195 with ( A ) the inward-open structure of human ABCB1 (PDBID:6QEX) and ( B ) structure of ABCG2 (PDB: 5NJ3) obtained after exhaustive docking using AutoDock Vina software as described in . TMP195 is presented as a molecular model with atoms colored as carbon–green, nitrogen–blue, oxygen–red, florine–white. The docking scores of the first nine poses (tighter binding) are shown on the left. Cartoon representation shows all nine binding poses in the side- and bottom-view of each transporter. Binding-cavity is shown in dark gray from the bottom-view, and TM helix numbers are specified. TMP195 is presented in green sticks. The lowest energy poses for TMP195 in the transmembrane region of ABCB1 and ABCG2 are presented in dark gray lines to illustrate the residues that are within 4 Å of the ligand. Figures were prepared using the Pymol molecular graphics system, Version 1.7 Shrödinger, LLC.

Journal: International Journal of Molecular Sciences

Article Title: The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

doi: 10.3390/ijms21010238

Figure Lengend Snippet: Docking of TMP195 in the drug-binding pockets of ABCB1 and ABCG2. Binding modes of TMP195 with ( A ) the inward-open structure of human ABCB1 (PDBID:6QEX) and ( B ) structure of ABCG2 (PDB: 5NJ3) obtained after exhaustive docking using AutoDock Vina software as described in . TMP195 is presented as a molecular model with atoms colored as carbon–green, nitrogen–blue, oxygen–red, florine–white. The docking scores of the first nine poses (tighter binding) are shown on the left. Cartoon representation shows all nine binding poses in the side- and bottom-view of each transporter. Binding-cavity is shown in dark gray from the bottom-view, and TM helix numbers are specified. TMP195 is presented in green sticks. The lowest energy poses for TMP195 in the transmembrane region of ABCB1 and ABCG2 are presented in dark gray lines to illustrate the residues that are within 4 Å of the ligand. Figures were prepared using the Pymol molecular graphics system, Version 1.7 Shrödinger, LLC.

Article Snippet: TMP195 is one of the most potent and highly selective class IIa histone deacetylase (HDAC) inhibitors identified by GlaxoSmithKline in an initiative to discover cell-active class IIa HDAC inhibitors [ ].

Techniques: Binding Assay, Software

Drug-sensitive parental and multidrug-resistant cells overexpressing ABCB1 or ABCG2 are equally sensitive to TMP195. The cytotoxicity of TMP195 was determined in ( A ) drug-sensitive human epidermal cancer cell line KB-3-1 (open circles) and KB-V-1, the ABCB1-overexpressing multidrug-resistant variant (filled circles), ( B ) drug-sensitive human ovarian cancer cell line OVCAR-8 (open circles) and NCI-ADR-RES, the ABCB1-overexpressing multidrug-resistant variant (filled circles), ( C ) drug-sensitive human colon cancer cell line S1 (open circles) and S1-M1-80, the ABCG2-overexpressing multidrug-resistant variant (filled circles), ( D ) drug-sensitive human lung cancer cell line H460 (open circles) and H460-MX20, the ABCG2-overexpressing multidrug-resistant variant (filled circles), as well as ( E ) parental pcDNA-HEK293 cells (open circles) and HEK293 cells transfected with human ABCB1 (MDR19-HEK293, filled circles) or human ABCG2 (R482-HEK293, open squares). Points, mean values from at least three independent experiments; error bars; SD.

Journal: International Journal of Molecular Sciences

Article Title: The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

doi: 10.3390/ijms21010238

Figure Lengend Snippet: Drug-sensitive parental and multidrug-resistant cells overexpressing ABCB1 or ABCG2 are equally sensitive to TMP195. The cytotoxicity of TMP195 was determined in ( A ) drug-sensitive human epidermal cancer cell line KB-3-1 (open circles) and KB-V-1, the ABCB1-overexpressing multidrug-resistant variant (filled circles), ( B ) drug-sensitive human ovarian cancer cell line OVCAR-8 (open circles) and NCI-ADR-RES, the ABCB1-overexpressing multidrug-resistant variant (filled circles), ( C ) drug-sensitive human colon cancer cell line S1 (open circles) and S1-M1-80, the ABCG2-overexpressing multidrug-resistant variant (filled circles), ( D ) drug-sensitive human lung cancer cell line H460 (open circles) and H460-MX20, the ABCG2-overexpressing multidrug-resistant variant (filled circles), as well as ( E ) parental pcDNA-HEK293 cells (open circles) and HEK293 cells transfected with human ABCB1 (MDR19-HEK293, filled circles) or human ABCG2 (R482-HEK293, open squares). Points, mean values from at least three independent experiments; error bars; SD.

Article Snippet: TMP195 is one of the most potent and highly selective class IIa histone deacetylase (HDAC) inhibitors identified by GlaxoSmithKline in an initiative to discover cell-active class IIa HDAC inhibitors [ ].

Techniques: Variant Assay, Transfection

Cytotoxicity of  TMP195  in human cell lines overexpressing ABCB1 or ABCG2.

Journal: International Journal of Molecular Sciences

Article Title: The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

doi: 10.3390/ijms21010238

Figure Lengend Snippet: Cytotoxicity of TMP195 in human cell lines overexpressing ABCB1 or ABCG2.

Article Snippet: TMP195 is one of the most potent and highly selective class IIa histone deacetylase (HDAC) inhibitors identified by GlaxoSmithKline in an initiative to discover cell-active class IIa HDAC inhibitors [ ].

Techniques:

A simplified schematic diagram of TMP195 reversing drug resistance in cancer cells overexpressing ABCB1 or ABCG2 by attenuating the function of ABCB1 and ABCG2. The ATP-binding cassette proteins ABCB1 (brown) and ABCG2 (green) reduce intracellular drug concentration by actively transporting ABCB1 substrate drug (red circles) and ABCG2 substrate drug (blue circles) out of the cancer cell, which leads to multidrug resistant phenotype. By binding to the drug-binding pocket(s) of ABCB1 and ABCG2, TMP195 (triangle) attenuates the drug efflux function of both ABCB1 and ABCG2, thus restoring the chemosensitivity of cancer cells to these chemotherapeutic drugs.

Journal: International Journal of Molecular Sciences

Article Title: The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

doi: 10.3390/ijms21010238

Figure Lengend Snippet: A simplified schematic diagram of TMP195 reversing drug resistance in cancer cells overexpressing ABCB1 or ABCG2 by attenuating the function of ABCB1 and ABCG2. The ATP-binding cassette proteins ABCB1 (brown) and ABCG2 (green) reduce intracellular drug concentration by actively transporting ABCB1 substrate drug (red circles) and ABCG2 substrate drug (blue circles) out of the cancer cell, which leads to multidrug resistant phenotype. By binding to the drug-binding pocket(s) of ABCB1 and ABCG2, TMP195 (triangle) attenuates the drug efflux function of both ABCB1 and ABCG2, thus restoring the chemosensitivity of cancer cells to these chemotherapeutic drugs.

Article Snippet: TMP195 is one of the most potent and highly selective class IIa histone deacetylase (HDAC) inhibitors identified by GlaxoSmithKline in an initiative to discover cell-active class IIa HDAC inhibitors [ ].

Techniques: Binding Assay, Concentration Assay